Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

September 12, 2023: MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies

MaaT Pharma and Skyepharma Complete Construction of Europe's Largest Manufacturing Facility for Microbiome Ecosystem Therapies…
Press Releases
September 8, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Press Releases
September 7, 2023: MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation Aiming to Improve Overall Survival in Patients Undergoing Hematopoietic Stem Cell transplantation
Press Releases
August 2, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Press Releases
July 27 2023: MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results

See more

Media Coverage

Media

September 19, 2023: Le Point – Traitement des cancers : le microbiote intestinal passe en phase industrielle (French only)

Media
September 13, 2023: Endpoints News – MaaT Pharma and CDMO Skyepharma unveil bespoke, and potentially largest, microbiome facility in Europe
Media
July 7, 2023: France 2- Les pouvoirs extraordinaires du corps humain (French only)
Media
April 28, 2023: Microbiome Times – FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013
Media
April 28, 2023: Microbiome Post – MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
Media
April 25, 2023: BioPharma Reporter – FDA lifts 18-month clinical hold on MaaT Pharma’s microbiome therapeutic

See more

Posters

Posters

Benchmarking of shotgun metagenomics analysis results obtained with state-of-the-art optimized pipelines on simulated gut microbiome samples

Posters
Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial
Posters
Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program
Posters
Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033
Posters
Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes
Posters
EBMT 2020: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics

Videos

Videos

R&D Day 2022 replay

On June 7th, 2022, MaaT Pharma hosted its virtual R&D Day to share the latest…
Videos
H.C Wainwright Bioconnect 2022 conference replay
Videos
Investors Webcast – 12/13/21 – Corporate Update
Videos
IABS Bioaster – FMT WEBINAR
Videos
EY : Prix de l’Entrepreneur de l’Année
Videos
Hybridays 2021: Savita BERNAL, Chief Business Officer at MaaT Pharma